Triple-Drug attack on Hard-to-Treat cancers shows early promise

NCT ID NCT02453620

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This early-phase study tests the safety and best doses of three drugs—entinostat, nivolumab, and ipilimumab—given together to people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to see if this combination can help the immune system fight cancer more effectively. About 57 adults with certain types of breast cancer or other solid tumors will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Smilow Cancer Center/Yale-New Haven Hospital

    New Haven, Connecticut, 06510, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.